Még nem toboroz
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· 3. fázis· Forrás
Még nem toboroz
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
2025-524969-24-00· 3. fázis· Forrás
Még nem toboroz
Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG
2026-525324-26-00· 2. fázis· Forrás
Toboroz
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· 3. fázis· Forrás
Toboroz
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
NCT05314998· 3. fázis· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07481981· 3. fázis· Forrás
Toboroz
CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids.
2025-520571-66-00· 3. fázis· Forrás
Toboroz
Anti-B-cell therapy in RA-ILD
2025-524872-51-00· 4. fázis· Forrás
Toboroz
Discontinuation Outcome in Multiple Myeloma after BCMA-CD3 treatment
2025-524022-18-00· 2. fázis· Forrás
Toboroz
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)
2025-524002-16-00· 3. fázis· Forrás
Toboroz
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT07660614· 1/2. fázis· Forrás
Toboroz
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709· 3. fázis· Forrás
Toboroz
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· 3. fázis· Forrás
Toboroz
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203· 3. fázis· Forrás
Toboroz
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· 3. fázis· Forrás
Toboroz
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA
2024-512922-27-00· 2. fázis· Forrás
Toboroz
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835· 2. fázis· Forrás
Toboroz
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· 3. fázis· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Forrás
Toboroz
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· 3. fázis· Forrás
Toboroz
SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma
2024-519593-39-00· 3. fázis· Forrás
Toboroz
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
NCT07187570· 3. fázis· Forrás
Toboroz
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· 3. fázis· Forrás
Fut, nem toboroz
A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
2024-518343-38-00· 3. fázis· Forrás
Toboroz
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune)
2023-506998-35-00· 3. fázis· Forrás
Toboroz
Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
NCT06488482· 3. fázis· Forrás
Toboroz
Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial (DISRITUX)
2023-508398-10-00· 4. fázis· Forrás
Fut, nem toboroz
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984· 3. fázis· Forrás
Fut, nem toboroz
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481· 2. fázis· Forrás
Toboroz
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
NCT06565247· 3. fázis· Forrás
Fut, nem toboroz
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· 2/3. fázis· Forrás
Toboroz
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277· 3. fázis· Forrás
Toboroz
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
NCT05852704· 3. fázis· Forrás
Toboroz
A Randomised study comparing Lutetium-177 versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer in PSMA positive patients.
2022-500570-33-00· 3. fázis· Forrás
Toboroz
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966· 3. fázis· Forrás
Toboroz
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT06262438· 2. fázis· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· 3. fázis· Forrás
Még nem toboroz
First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation
NCT05939076· 3. fázis· Forrás
Toboroz
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
2023-504999-25-00· 3. fázis· Forrás
Meghívásos bevonás
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
NCT05697861· 2/3. fázis· Forrás
Toboroz
Use of GnRHa During Chemotherapy for Fertility Protection
NCT05328258· 3. fázis· Forrás
Toboroz
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
NCT05284552· 2. fázis· Forrás
Toboroz
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00· 3. fázis· Forrás
Toboroz
ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study
2024-518172-31-01· 3. fázis· Forrás
Fut, nem toboroz
Methotrexate in Patients with Early Rheumatoid Arthritis
NCT05353829· 4. fázis· Forrás
Toboroz
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
NCT04920149· 2. fázis· Forrás
Fut, nem toboroz
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
NCT05214183· 2. fázis· Forrás
Fut, nem toboroz
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· 3. fázis· Forrás
Fut, nem toboroz
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
NCT04647526· 3. fázis· Forrás
Toboroz
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· 1/2. fázis· Forrás